Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Cypher Genomics Ink Co-marketing Agreement

NEW YORK (GenomeWeb) – Cypher Genomics has signed a co-promotion agreement with Illumina that lets the sequencing vendor offer Cypher's Coral biomarker discovery service to pharmaceutical companies.

Specifically, under the terms of the agreement, Illumina's sales force will market Coral as part of a solution to pharma that includes sequencing and its NextBio platform for data analytics and storage. Pharma firms could, for example, use the service to analyze small groups of patients in early clinical trials to discover genetic markers that are linked to therapeutic response.

In a statement, Nick Naclerio, Illumina's senior vice president for corporate development and general manager for enterprise informatics, described Cypher's biomarker discovery service is "a perfect complement" to Illumina's offerings.

The combined offering will enable pharma companies to accelerate "their personalized drug development efforts and … ultimately help deliver on the promise of precision medicine," Adam Simpson, Cypher's president and chief operating officer, added.

Financial and other terms of the agreement were not disclosed.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.